BioMarin Pharmaceutical (BMRN) reported new data from an investigator-led analysis of the Phase 2 111-205 study, which showed that children with achondroplasia treated with VOXZOGO experienced increases in bone length while maintaining bone strength. The analysis, after approximately five years of therapy, suggested that treatment allowed the bone to remain strong as it lengthened.
VOXZOGO is approved in the U.S. and Japan to increase linear growth in children of all ages with achondroplasia with open epiphyses. In the U.S., the indication is approved under accelerated approval based on an improvement in annualized growth velocity.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.